MIPLYFFA
Growtharimoclomol citrate
NDAORALCAPSULEPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIPLYFFA (arimoclomol citrate) is an oral capsule approved in September 2024 for heat shock protein inducer therapy. The drug mechanism and specific indications are not yet publicly detailed in this dataset. Patient outcomes depend on the indication for which it was approved.
Growth3.4 years to LOE
Early-stage product in growth phase with limited current market data; Commercial teams are building launch infrastructure with competitive pressure score of 8/10.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.